Mechanisms of the cardiac/vasculor hypertrophy and cardio-protection

1)血管紧张素转换酶（ACE）在心肌梗死区明显升高，在肥厚心肌中升高更为明显，但与假手术组相比，ACE亲和力无明显变化。本研究证实心脏ACE可能参与了慢性心力衰竭心肌肥厚的病理生理过程。2）研究了f-Met-Leu-Phe（FMLP）在人冠状动脉中的作用及其细胞机制。逆转录-聚合酶链反应（RT-PCR）显示相对于白细胞，FMLP受体同源物FPRH 1和FPRH 2 mRNA在人冠状动脉中膜组织中的主要表达。3）我们评估了长效抗高血压药物（氯沙坦5 mg/kg/天，咪达普利5 mg/kg/天p.o.，经口给药≤ 5 mg/kg/天在饮用溶液中12周）在慢性肾衰竭大鼠中。结果表明，这些长效降压药对CRF大鼠的心、肾功能具有同等的保护作用，并提示激肽释放酶-激肽系统在ACE抑制剂对CRF大鼠的心、肾保护作用中可能不起主要作用。和血管紧张素转化酶抑制剂依那普利（2 mg/kg/天i. p.），结合适度运动对慢性肾功能衰竭大鼠的影响。适度运动可保护该模型的肾功能。他们还表明，FR 139317在这种运动模型中可能没有额外的抗高血压和肾脏保护作用。

1) Angiotensin converting enzyme (ACE) increased markedly in the infarct area and modetately in hypertrophied myocardium without changing the affinity compared to the sham-operated rats. The study confirms that cardiac ACE may participate in the pathophysiology of cardiac hypertrophy in chronic heart failure.2) We investigated the actions of f-Met-Leu-Phe (FMLP) and its cellular mechamism in human coronary arteries. A reverse transcription-polymerase chain reaction (RT-PCR) showed predominent expression of FMLP receptor homologues, FPRH1 and FPRH2 mRNA,in human coronary medial tissue relative to that in leukocytes.3) We assessed the renal-protective effect of long-acting antihypertensive drugs (losartan 5 mg/kg/day p.o., imidapril 5 mg/kg/day p.o., amlodipine 5 mg/kg/day p.o. ; in drinking solution for 12 weeks) in rats with chronic renal failure. The results indicate that these long-acting antihypertensive drugs equally have potency to protrct heart and kidney in rats with CRF.They also indicate that the kallikrein-kinin system might not play a major role in the cardio-and reno-protective effects of ACE inhibitors in rats with CRF.4) Chronic administration of a specific endothelin subtype A receptor antagonist, FR139317 (32 mg/kg/day i.p.) and an angiotensin converting enzyme inhibitor, enalapril (2mg/kg/day i.p.), in combination with moderate exercise were investigated in rats with chronic renal failure. Moderate exercise may protect renal function in this model. They also suggest that FR139317 may not have an additional antihypertensive and renal protective effect in this exercise model.